Highlights of weekly biotech stock moves

Celgene Corp. (NASDAQ:CELG) was up $0.70 to $78.42 on Friday after FDA approved an sNDA for Abraxane nab-paclitaxel for first-line treatment of advanced non-small cell lung cancer (NSCLC). The product was first approved in the U.S. in 2005 to treat metastatic breast cancer.

Earlier in the week, EMA's CHMP reiterated that it needs mature overall survival data before it can make a decision on whether to approve an expanded label for multiple myeloma (MM) drug Revlimid lenalidomide (see B13)...